RT Journal Article
T1 Cellular immune activity biomarker neopterin is associated hyperlipidemia: results from a large population-based study.
A1 Chuang, Shu-Chun
A1 Boeing, Heiner
A1 Vollset, Stein Emil
A1 Midttun, Øivind
A1 Ueland, Per Magne
A1 Bueno-de-Mesquita, Bas
A1 Lajous, Martin
A1 Fagherazzi, Guy
A1 Boutron-Ruault, Marie-Christine
A1 Kaaks, Rudolf
A1 Küehn, Tilman
A1 Pischon, Tobias
A1 Drogan, Dagmar
A1 Tjønneland, Anne
A1 Overvad, Kim
A1 Quirós, J Ramón
A1 Agudo, Antonio
A1 Molina-Montes, Esther
A1 Dorronsoro, Miren
A1 Huerta, José María
A1 Barricarte, Aurelio
A1 Khaw, Kay-Tee
A1 Wareham, Nicholas J
A1 Travis, Ruth C
A1 Trichopoulou, Antonia
A1 Lagiou, Pagona
A1 Trichopoulos, Dimitrios
A1 Masala, Giovanna
A1 Agnoli, Claudia
A1 Tumino, Rosario
A1 Mattiello, Amalia
A1 Peeters, Petra H
A1 Weiderpass, Elisabete
A1 Palmqvist, Richard
A1 Ljuslinder, Ingrid
A1 Gunter, Marc
A1 Lu, Yunxia
A1 Cross, Amanda J
A1 Riboli, Elio
A1 Vineis, Paolo
A1 Aleksandrova, Krasimira
K1 Cell-mediated immunity
K1 Metabolic syndrome
K1 Neopterin
AB Increased serum neopterin had been described in older age two decades ago. Neopterin is a biomarker of systemic adaptive immune activation that could be potentially implicated in metabolic syndrome (MetS). Measurements of waist circumference, triglycerides, high-density lipoprotein cholesterol (HDLC), systolic and diastolic blood pressure, glycated hemoglobin as components of MetS definition, and plasma total neopterin concentrations were performed in 594 participants recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC). Higher total neopterin concentrations were associated with reduced HDLC (9.7 %, p  These data suggest that high total neopterin concentrations are cross-sectionally associated with reduced HDLC, but not with overall MetS.
SN 1742-4933
YR 2016
FD 2016-02-25
LK https://hdl.handle.net/10668/24701
UL https://hdl.handle.net/10668/24701
LA en
DS RISalud
RD Apr 18, 2025